Outlook Therapeutics (NASDAQ:OTLK) Releases Earnings Results

Outlook Therapeutics (NASDAQ:OTLK) issued its quarterly earnings data on Friday. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.04), Zacks reports.

Outlook Therapeutics Trading Up 1.6 %

NASDAQ:OTLK opened at $1.87 on Friday. Outlook Therapeutics has a one year low of $0.87 and a one year high of $12.85. The business’s 50-day simple moving average is $1.88 and its 200 day simple moving average is $4.47.

Analysts Set New Price Targets

A number of research analysts have commented on the company. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Outlook Therapeutics in a research note on Friday, January 17th. BTIG Research reduced their price objective on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. Guggenheim reiterated a “buy” rating and issued a $12.00 price target on shares of Outlook Therapeutics in a research note on Friday, January 17th. Finally, Chardan Capital reiterated a “neutral” rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Outlook Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $27.40.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.